Last reviewed · How we verify
NCT02268539
Efficacy, Safety and Efficiency of the nMARQ Pulmonary Vein Isolation System in Paroxysmal Atrial Fibrillation
NA trial testing ablation in Paroxysmal Atrial Fibrillation in 11 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | Mid and South Essex NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 1 February 2014 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- ablation
Conditions studied
- Paroxysmal Atrial Fibrillation — all drugs for Paroxysmal Atrial Fibrillation →
Sponsor
Mid and South Essex NHS Foundation Trust
Who can join
Adults 18 to 80, any sex, with Paroxysmal Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study designed to investigate the effectiveness of the nMARQ Pulmonary Vein Isolation system in the treatment of Paroxysmal Atrial Fibrillation (AF) at different ablation settings. AF is a common condition which causes a fast and erratic heartbeat. There are estimated to be 50,000 new cases diagnosed per year in the UK. The fast heart beat can cause symptoms such as palpitations, lightheadedness, chest pains, shortness of breath and fatigue. Catheter ablation is a technique used for the control of AF. In this procedure a catheter (a long thin wire) is passed into the chambers of the heart via a large blood vessel in a leg. The tip of the catheter can destroy tiny sections of heart tissue that may be the source or trigger of the abnormal electrical impulses. One of the challenges of AF ablation is to maximize success rates, as such there is currently rapid advances in technology to carry out this procedure. Different catheters exist which deliver this energy in different ways. This study uses one such system to perform this procedure. It is called the nMARQ system for Pulmonary Vein Isolation produced by Biosense Webster. Currently this system is used in practice in the UK for patients with this medical condition. What we seek to research is when ablating what is the optimum setting to perform ablation at. There is currently no data to guide best clinical practice in this area.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02268539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ablation
Trials testing the same drug.
- NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
- NCT07487662 — TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcin · Phase 2 · not yet recruiting
- NCT07503769 — CHU Dual-Energy Ablation in Ventricular Arrhythmia · NA · enrolling by invitation
- NCT05803928 — Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies · Phase 1 · recruiting
- NCT05643209 — Brugada Syndrome Substrate Characterization and Ablation · NA · recruiting
Other recruiting trials for Paroxysmal Atrial Fibrillation
Currently open trials in the same condition.
- NCT07535268 — REPRESENT-PF Registry · recruiting
- NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
- NCT07281898 — Burst Stimulation for Paroxysmal Atrial Fibrillation · NA · recruiting
- NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
- NCT06765356 — Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias · Phase 4 · active not recruiting
Other Mid and South Essex NHS Foundation Trust trials
Trials by the same sponsor.
- NCT06702306 — Duplex UltraSound afTer Endo Revascularisation - Feasibility Randomised Control Trial (DUSTER) · NA · active not recruiting
- NCT07173426 — Bioimpedance Integration for Optimized Fluid Management in Decompensated Heart Failure · NA · recruiting
- NCT06628115 — Post Market Study of Cerament V/G in Pedal Osteomyelitis · NA · not yet recruiting
- NCT06247761 — STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery · NA · unknown
- NCT05035771 — The IMPACT PAD Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02268539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mid and South Essex NHS Foundation Trust
- Last refreshed: 22 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02268539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing